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MicroRNA-143 and -145 modulate the phenotype
of synovial ﬁbroblasts in rheumatoid arthritis
Bong-Ki Hong1, Sungyong You2, Seung-Ah Yoo1, Dohyun Park1, Daehee Hwang3, Chul-Soo Cho1,4
and Wan-Uk Kim1,4
Fibroblast-like synoviocytes (FLSs) constitute a major cell subset of rheumatoid arthritis (RA) synovia. Dysregulation of
microRNAs (miRNAs) has been implicated in activation and proliferation of RA-FLSs. However, the functional association of
various miRNAs with their targets that are characteristic of the RA-FLS phenotype has not been globally elucidated. In this
study, we performed microarray analyses of miRNAs and mRNAs in RA-FLSs and osteoarthritis FLSs (OA-FLSs), simultaneously,
to validate how dysregulated miRNAs may be associated with the RA-FLS phenotype. Global miRNA proﬁling revealed that
miR-143 and miR-145 were differentially upregulated in RA-FLSs compared to OA-FLSs. miR-143 and miR-145 were highly
expressed in independent RA-FLSs. The miRNA-target prediction and network model of the predicted targets identiﬁed insulin-
like growth factor binding protein 5 (IGFBP5) and semaphorin 3A (SEMA3A) as potential target genes downregulated by
miR-143 and miR-145, respectively. IGFBP5 level was inversely correlated with miR-143 expression, and its deﬁciency rendered
RA-FLSs more sensitive to TNFα stimulation, promoting IL-6 production and NF-κB activity. Moreover, SEMA3A was a direct
target of miR-145, as determined by a luciferase reporter assay, antagonizing VEGF165-induced increases in the survival,
migration and invasion of RA-FLSs. Taken together, our data suggest that enhanced expression of miR-143 and miR-145
renders RA-FLSs susceptible to TNFα and VEGF165 stimuli by downregulating IGFBP5 and SEMA3A, respectively, and that
these miRNAs could be therapeutic targets.
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INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease that
is characterized by chronic inﬂammatory cell inﬁltration and
pannus formation in synovial tissues that lead to the destruc-
tion of articular cartilage and bone. In RA joints, various
inﬂammatory cells become activated via a variety of cytokines
and chemokines as well as via cell–cell contact.1 Among various
cell types, ﬁbroblast-like synoviocytes (FLSs) are the most
abundant resident cells in the synovial membrane and play
critical roles in the pathogenesis of RA. FLSs in an RA patient
(RA-FLSs) have tumor-like features, including an increased
proliferation rate, anti-apoptotic ability and pro-migratory and
pro-invasive properties that cause pannus formation and joint
destruction.2,3 Moreover, RA-FLSs produce large amounts of
pro-inﬂammatory cytokines, including interleukin-1β (IL-1β),
IL-6 and tumor necrosis factor α (TNFα), that contribute to
the perpetuation of chronic inﬂammation.2
MicroRNAs (miRNAs) have emerged as key regulators of a
broad spectrum of cellular functions, such as proliferation,
differentiation and apoptosis, that are associated with the
pathogenesis of various autoimmune diseases.4 Evidence is
emerging that miRNA expression is dysregulated in RA-FLSs,
which may be responsible for various pathologic processes
involving RA.5–8 For example, miR-126 has been identiﬁed
as a regulator of phosphatidylinositol 3-kinase (PI3K)/AKT
in RA-FLSs, an important signaling molecule mediating cell
proliferation and apoptosis.5 In addition, miR-20a has been
found to have two target genes in FLSs: thioredoxin interacting
protein (TXNIP) and apoptosis signal-regulating kinase
(ASK1).6,7 These mediate NLRP3-inﬂammasome and TLR4-
dependent cytokine release by FLSs, respectively.6,7 miR-221
has also been identiﬁed as a regulator for increased migration
and invasion of RA-FLSs.8 Nevertheless, global and integrated
analyses of miRNA and mRNA expression levels, which can
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